SVA [SINOVAC BIOTECH] 6-K: Sinovac Establishes Joint Venture to Expand Human-Use Vaccine

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2009-11-27
Original SEC Filing: Click here


Webplus: SVA/20091127/6-K/2_EX-99.1/000.htm SEC Original: a09-34417_1ex99d1.htm
Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities -Sinovac to Own 55% in Joint Venture by Year End 2010- BEIJING, Nov. 25 /PRNewswire-Asia/ — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines, announced today that it executed a joint venture (JV) agreement to establish Sinovac (Dalian) Vaccine Technology Co., Ltd. (Sinovac Dalian).




Webplus: SVA/20091127/6-K/1/000.htm SEC Original: a09-34417_16k.htm
01 – 32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.



Company Information:

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2009-11-27CIK: 0001084201, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
39 SHANGDI XI ROAD
BEIJING 100085

Home Page Forums

By | 2016-03-24T03:57:28+00:00 November 27th, 2009|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

About the Author:

Leave A Comment

Skip to toolbar